These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30865050)

  • 1. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.
    Minnis AM; Atujuna M; Browne EN; Ndwayana S; Hartmann M; Sindelo S; Ngcwayi N; Boeri M; Mansfield C; Bekker LG; Montgomery ET
    J Int AIDS Soc; 2020 Jun; 23(6):e25528. PubMed ID: 32544303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of South African youth in the development of an implant for HIV prevention.
    Krogstad EA; Atujuna M; Montgomery ET; Minnis A; Ndwayana S; Malapane T; Shapley-Quinn MK; Manenzhe K; Bekker LG; van der Straten A
    J Int AIDS Soc; 2018 Aug; 21(8):e25170. PubMed ID: 30152004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
    BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth.
    Montgomery ET; Browne EN; Atujuna M; Boeri M; Mansfield C; Sindelo S; Hartmann M; Ndwayana S; Bekker LG; Minnis AM
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):928-936. PubMed ID: 33633031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
    Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
    J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preference for novel biomedical HIV pre-exposure prophylaxis methods among adolescent girls and young women in Kampala, Uganda: a mixed methods study.
    Mayanja Y; Kayesu I; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Price M; Kosidou K; Ekström AM
    Front Public Health; 2024; 12():1369256. PubMed ID: 38846614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
    Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
    Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
    J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Client experiences with "Dynamic Choice Prevention," a model for flexible patient-centred HIV prevention delivery in rural Eastern Africa.
    Camlin CS; Arunga T; Johnson-Peretz J; Akatukwasa C; Atwine F; Onyango A; Owino L; Kamya MR; Petersen ML; Chamie G; Kakande E; Kabami J; Balzer LB; Havlir DV; Ayieko J
    J Int AIDS Soc; 2024 Jul; 27(7):e26336. PubMed ID: 39020454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland.
    Siedner MJ; Hettema A; Hughey A; Oldenburg CE; Kohler S; Bärnighausen K; McMahon S; Jia C; Lejeune C; Matse S; Bärnighausen T
    AIDS; 2018 Jul; 32(11):1541-1542. PubMed ID: 29794832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection.
    Vickerman P; Quaife M; Kilbourne-Brook M; Mvundura M; Eakle R; Terris-Prestholt F
    BMC Infect Dis; 2020 Sep; 20(1):704. PubMed ID: 32977745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implants for HIV prevention in young women: Provider perceptions and lessons learned from contraceptive implant provision.
    Humphries H; Upfold M; Mahlase G; Mdladla M; Gengiah TN; Abdool Karim Q
    PLoS One; 2022; 17(1):e0262043. PubMed ID: 35025908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.
    Krogstad EA; Montgomery ET; Atujuna M; Minnis AM; O'Rourke S; Ahmed K; Bekker LG; van der Straten A
    AIDS Patient Care STDS; 2019 Apr; 33(4):157-166. PubMed ID: 30932697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment.
    Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F
    BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
    Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
    Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.
    Little KM; Flomen L; Hanif H; Anderson SM; Thurman AR; Clark MR; Doncel GF
    AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iPrevent: Engaging youth as long-acting HIV prevention product co-researchers in Cape Town, South Africa.
    Hartmann M; Minnis AM; Krogstad E; Ndwayana S; Sindelo S; Atujuna M; O'Rourke S; Bekker LG; Montgomery ET
    Afr J AIDS Res; 2021 Dec; 20(4):277-286. PubMed ID: 34905456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.